Cargando…

Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9?

BACKGROUND: Serum small dense LDL-cholesterol (sdLDL-C) value is suggested to bean important risk factor for atherosclerosis. Since sdLDL-C changes may be related to PCSK9 and SREBP-2 functions, the aim of this study was to investigate correlations between sdLDL-C, circulating PCSK9, SREBP-2 express...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soltanmohammadi, Elham, Piran, Sadegh, Mohammadi, Asghar, Hosseni, Bita, Naseri, Faezeh, Shabani, Mohammad, Najafi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Medical Biochemists of Serbia 2016
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471636/ https://www.ncbi.nlm.nih.gov/pubmed/28670193 http://dx.doi.org/10.1515/jomb-2016-0019

Ejemplares similares

Cytokeratin 8 in Association with sdLDL and ELISA Development
por: Ashmaig, Mohmed
Publicado: (2015)

Precipitated sdLDL: An easy method to estimate LDL particle size
por: Fernández‐Cidón, Bárbara, et al.
Publicado: (2020)

PCSK9 positively correlates with plasma sdLDL in community-dwelling population but not in diabetic participants after confounder adjustment
por: Liu, Yan, et al.
Publicado: (2019)

Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Comparison of seven different reagents of peroxidase method for small and dense low density lipoprotein cholesterol (sdLDL‐C) measurement
por: Xuesong, Fan, et al.
Publicado: (2020)

Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma
por: Guo, Yi, et al.
Publicado: (2021)

Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C
por: Li, Sha, et al.
Publicado: (2016)

Combined Effect of Small Dense Low-Density Lipoprotein Cholesterol (sdLDL-C) and Remnant-Like Particle Cholesterol (RLP-C) on Low-Grade Inflammation
por: Izumida, Toshihide, et al.
Publicado: (2020)

Estimated sdLDL-C for predicting high-risk coronary plaque features in psoriasis: a prospective observational study
por: Sorokin, Alexander V., et al.
Publicado: (2023)

High sdLDL Cholesterol can be Used to Reclassify Individuals with Low Cardiovascular Risk for Early Intervention: Findings from the Chinese Multi-Provincial Cohort Study
por: Qi, Yue, et al.
Publicado: (2020)

MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy
por: Tian, Yong, et al.
Publicado: (2021)

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
por: Zhang, Liwen, et al.
Publicado: (2012)

Investigation of galectin-3, lipocalin 2, retinol binding protein (RBP), small dense low-density lipoprotein (sdLDL) in patients with hirsutism
por: Yavuz, Ibrahim Halil, et al.
Publicado: (2019)

LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study
por: Imajo, Kento, et al.
Publicado: (2014)

Clinical significance of neutrophil gelatinase-associated lipocalin and sdLDL-C for coronary artery disease in patients with type 2 diabetes mellitus aged ≥ 65 years
por: Chen, Yanhong, et al.
Publicado: (2022)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
por: Bandyopadhyay, Dhrubajyoti, et al.
Publicado: (2018)

Legacy perfluoro-alkyl substances impair LDL-cholesterol uptake independently from PCSK9-function
por: Sabovic, Iva, et al.
Publicado: (2023)

Increased LDL receptor by SREBP2 or SREBP2-induced lncRNA LDLR-AS promotes triglyceride accumulation in fish
por: Cao, Xiufei, et al.
Publicado: (2022)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
por: Gadkar, K, et al.
Publicado: (2014)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
por: Benn, Marianne, et al.
Publicado: (2017)

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
Publicado: (2017)

A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates
por: Fowler, Alexandra, et al.
Publicado: (2023)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study
por: Eshraghian, Ahad, et al.
Publicado: (2021)

Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1α/SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression
por: Lin, Yen-Kuang, et al.
Publicado: (2021)

miR-27a inhibits molecular adhesion between monocytes and human umbilical vein endothelial cells; systemic approach
por: Shaikhnia, Farhad, et al.
Publicado: (2022)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody: Randomized, Placebo-Controlled Phase 1 Studies
por: Cui, Yimin, et al.
Publicado: (2021)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m8hl6eslbds0otv35i6e75fdjv